title: [Observations on clinic curative effect of oxymatrine to cure hemorrhagic fever with renal syndrome (HFRS)].
abstract: OBJECTIVE
  To observe the curative effect of oxymatrine to cure hemorrhagic fever with renal syndrome.
  
  
  METHODS
  Randomly divide 418 patients suffering from hemorrhagic fever with renal syndrome into a treatment group and a control group, use oxymatrine to give an intravenous drip to the patients in the treatment group, one time a day, each time 600 mg, lasting for 7 days as one period of treatment and meanwhile take a traditional equilibrium salt treatment for the patients in the control group. Observe the change of the illness in both groups and occurrence of complications, dynamically test the magnitude of serum urination-regulated protein (THP) and beta(2) microglobulin (beta(2)M) of the patients, in the meantime observe the change in magnitude of serum white blood cell medium 15 (IL-15) and soluble intercellular adhesion molecules (sICAM-1).
  
  
  RESULTS
  Shorten the course of the disease of the patients in the oxymatrine treatment group, make an improvement after the recovery and obviously reduce the magnitude of serum urination-regulated protein (THP) and beta(2) microglobulin and show a striking difference in magnitude of serum IL-15 and sICAM-1 after the treatment compared with that of the patients in the control group.
  
  
  CONCLUSIONS
  Oxymatrine has a certainly true curative effect to hemorrhagic fever with renal syndrome and worth of furthering its widespread use in clinics.
authors.affiliation: Department of Infectious Diseases, Heilongjiang Provincial Hospital, Harbin 150036, China.
authors.forename: Zhong-qing
authors.initials: ZQ
authors.lastname: Yu
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Qing-you
authors.initials: QY
authors.lastname: Zeng
authors.forename: Li-Yan
authors.initials: LY
authors.lastname: Chen
authors.forename: Jian-xun
authors.initials: JX
authors.lastname: Wang
authors.forename: Jian-xun
authors.initials: JX
authors.lastname: Yang
authors.forename: Shu-hua
authors.initials: SH
authors.lastname: Li
authors.forename: Bao-shan
authors.initials: BS
authors.lastname: Yang
mesh_terms: D000328:Adult; D000470:Alkaloids / Q000627:therapeutic use*; D005260:Female; D006480:Hemorrhagic Fever with Renal Syndrome / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D019409:Interleukin-15 / Q000097:blood; D008297:Male; D011807:Quinolizines / Q000627:therapeutic use*; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000378:metabolism; D000093842:Matrines
chemical_list: D000470:Alkaloids; D018799:Intercellular Adhesion Molecule-1; D019409:Interleukin-15; D011807:Quinolizines; D001613:beta 2-Microglobulin; C037573:oxymatrine; D000093842:Matrines